Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
Saved in:
| Title: | Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. |
|---|---|
| Authors: | Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: motzerr@mskcc.org., Powles T; Department of Genitourinary Oncology, Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free National Health Service Trust, London, UK., Burotto M; Bradford Hill Clinical Research Center, Santiago, Chile., Escudier B; Department of Medical Oncology, Gustave Roussy, Villejuif, France., Bourlon MT; Department of Hemato-Oncology, Urologic Oncology Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Shah AY; Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA., Suárez C; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Hamzaj A; Department of Medical Oncology, Ospedale San Donato, Istituto Toscano Tumori, Arezzo, Italy., Porta C; Department of Internal Medicine, University of Pavia, Pavia, Italy; Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy., Hocking CM; Cancer Clinical Research Unit, Lyell McEwin Hospital, Elizabeth Vale, SA, Australia., Kessler ER; Division of Medical Oncology, Department of Internal Medicine, University of Colorado School of Medicine, Aurora, CO, USA., Gurney H; Department of Clinical Medicine, Macquarie University, Sydney, NSW, Australia., Tomita Y; Departments of Urology and Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan., Bedke J; Department of Urology, Eberhard Karls University Tübingen, Tübingen, Germany., Zhang J; Department of Clinical Research, Bristol Myers Squibb, Princeton, NJ, USA., Simsek B; Department of Global Biometrics and Data Science, Bristol Myers Squibb, Princeton, NJ, USA., Scheffold C; Department of Clinical Development, Exelixis, Alameda, CA, USA., Apolo AB; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Choueiri TK; Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA. |
| Source: | The Lancet. Oncology [Lancet Oncol] 2022 Jul; Vol. 23 (7), pp. 888-898. Date of Electronic Publication: 2022 Jun 07. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
